Linda Hentz
Acute Care · Lexington, SCNPI 1134632581
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 535 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 535 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$989
- AbbVie$987
- plus $3K from 16 others
What the payments were for
- Food & beverage$9,90297%
- Education$2633%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 109 | $1,594 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 62 | $1,477 |
| Neurocrine Biosciences, Inc. | 67 | $1,268 |
| Otsuka America Pharmaceutical, Inc. | 53 | $1,057 |
| Johnson & Johnson | 38 | $989 |
| AbbVie | 86 | $987 |
| Alkermes, Inc. | 28 | $834 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $271 |
| Indivior Inc. | 17 | $261 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $224 |
| E.r. Squibb & Sons, L.L.C. | 8 | $205 |
| Tris Pharma Inc | 10 | $176 |
| Lundbeck LLC | 7 | $125 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 5 | $124 |
| Supernus Pharmaceuticals, Inc. | 5 | $107 |
| Corium, LLC | 5 | $87 |
| Noven Therapeutics, LLC | 4 | $78 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Merck | 3 | $47 |
| Collegium Pharmaceutical, Inc. | 2 | $39 |
| Neos Therapeutics, LP | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,164 in reported general payments places this provider in the 95th percentile of 339 acute care providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 30 | $247,167 |
| Invega SustennaPaliperidone Palmitate | 40 | $133,055 |
| Abilify MaintenaAripiprazole | 12 | $35,784 |
| RexultiBrexpiprazole | 11 | $16,276 |
| Naltrexone Hcl | 12 | $941 |
| Duloxetine Hcl | 44 | $833 |
| Hydroxyzine Pamoate | 40 | $772 |
| Haloperidol | 18 | $633 |
| Quetiapine Fumarate | 40 | $604 |
| Buspirone Hcl | 36 | $581 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 44 | $522 |
| Hydroxyzine Hcl | 30 | $476 |
| Ramelteon | 11 | $446 |
| Lamotrigine | 42 | $408 |
| Aripiprazole | 30 | $402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,268 | $247,16730 claims |
| Johnson & JohnsonInvega Sustenna | $989 | $133,05540 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,057 | $52,06023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 acute care providers in South Carolina.
Other acute care in Lexington
- Barbara GrubbsLexington$3K
- Heather BowersGreenville$94K
- Michael GajewskiColumbia$62K
- Heather NortonMt Pleasant$57K
- Cameron ThomassonSumter$28K
- Sarah MatthewsGreenville$28K
- Micheal BungerColumbia$15K
- Robin TrauflerColumbia$12K
- Susan FunkGreenville$11K
- Kylie CapdevilaFlorence$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.